CTXR · Citius Pharmaceuticals, Inc.
$0.60
+0.03 (+4.92%)
At close · Aug 25
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We will need to raise additional capital in the future to support our operations beyond November 2026, which raises substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$16.57M
Shares
27.45M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.60
Open$0.58
Day$0.58–0.67
52W close$0.48–1.82
Avg vol 30d874K
Short int5.4M · 19.5% float · 5.3d
Short vol56%
Last earningsAug 13, 2024
DataNov 2024–Aug 2026
Filing10-Q · Aug 14
Raw chart and full-history price indicators begin at the captured split on Nov 26, 2024; bars on opposite sides are not compared.
Up next
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−23%
below
Price vs 50-day avg
+3%
above
RSI (14)
49
neutral
MACD trend
Negative
52-week position
9%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+21%
trailing
6-month return
−26%
trailing
YTD return
−22%
this year
Relative strength
−38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
19.55% of float · ▲ +4.0% MoM · 5.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
43 holders — mid 3-yr range
Squeeze score
80
high risk · 0–100
Fundamentals
EPS growth
+43%
Y/Y
Free cash flow
$-26.6M
Balance sheet
$3.7M
net cash
Quant / Vol
risk profile
Volatility
113%
annualized · 1-yr
Max drawdown
−74%
past year
ATR
12.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−23%
Bearish
Price vs 50-day avg
+3%
Bullish
RSI (14)
49
Neutral
MACD trend
Negative
Bearish
52-week position
9%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
19.55% of float · ▲ +4.0% MoM · 5.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
43 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $1 · 9%
Range high $2
vs 200-day avg -23%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Citius Oncology commercial and medical affairs team professionals | 29 | fiscal third quarter 2026 | — |
| Citius Oncology senior secured term loan facility | $25M | fiscal third quarter 2026 | — |
| Gross margin for the nine months ended June 30, 2026 | 77% | the nine months ended June 30, 2026 | — |
| Gross margin for the three months ended June 30, 2026 | 67% | the three months ended June 30, 2026 | — |
| LYMPHIR availability in institutions | 44 | fiscal third quarter 2026 | — |
| LYMPHIR clinical benefit rate in combination with pembrolizumab in recurrent or refractory gynec | 48% | fiscal third quarter 2026 | — |
| LYMPHIR complete response (CR) rate prior to CAR-T therapy in high-risk relapsed or refractory D | 57% | fiscal third quarter 2026 | — |
| LYMPHIR institutional vial orders growth | 31% | fiscal third quarter 2026 | — |
| LYMPHIR new institutions ordering growth | 80% | fiscal third quarter 2026 | — |
| LYMPHIR overall response rate (ORR) in combination with pembrolizumab in recurrent or refractory | 24% | fiscal third quarter 2026 | — |
| LYMPHIR overall response rate (ORR) prior to CAR-T therapy in high-risk relapsed or refractory D | 86% | fiscal third quarter 2026 | — |
| LYMPHIR vials ordered by institutions from wholesalers in July | 383 | July 2026 | — |
| gross margins | 80% | Fiscal Second Quarter 2026 | — |
| of target accounts had added or were actively progressing LYMPHIR through formulary review | 83% | Fiscal Second Quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTXR
this stock
Citius Pharmaceuticals, Inc.
|
$16.57M | -22.3% | +0.0% | — | 19.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.79B | +21.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.30B | +8.0% | +20.8% | 20.5 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +21.2% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Nov 26, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTXR | +5.5% | +21.2% | -26.0% | +5.9% | -22.3% |
| SPY | -0.2% | +3.4% | +11.8% | +2.5% | +12.3% |
| vs SPY | +5.7% | +17.8% | -37.8% | +3.4% | -34.6% |